Table 2.
Characteristics of first allo-HSCT
| Characteristics | No. (%) of cases with available information | Overall | LAD type I | LAD type III | P |
|---|---|---|---|---|---|
| N (%) | 84 (100) | 69 (82) | 11 (13) | ||
| Allo-HSCT y, n (%) | 84 (100) | 1 | |||
| 2007-2012 | 41 (49) | 34 (49) | 5 (45) | ||
| 2013-2017 | 43 (51) | 35 (51) | 6 (55) | ||
| Age at allo-HSCT, mo | 84 (100) | .872 | |||
| Median | 13 | 12 | 15 | ||
| IQR | 0-29 | 6-32 | 8-29 | ||
| Range | 1-354 | 1-354 | 2-95 | ||
| Lansky/Karnofsky performance, n (%) | 63 (75) | .560 | |||
| Score 100 | 22 (35) | 18 (35) | 3 (43) | ||
| Score 90 | 22 (35) | 19 (37) | 1 (14) | ||
| Score 80 | 16 (25) | 12 (23) | 3 (43) | ||
| Score 70 | 1 (2) | 1 (2) | 0 | ||
| Score 60 | 2 (3) | 2 (4) | 0 | ||
| Allo-HSCT source, n (%) | 80 (95) | .267 | |||
| BM | 44 (55) | 38 (58) | 4 (40) | ||
| CB | 16 (20) | 10 (15) | 4 (40) | ||
| PB | 20 (25) | 18 (27) | 2 (20) | ||
| Donor, n (%) | 82 (98) | .419 | |||
| MSD | 32 (39) | 29 (43) | 3 (27) | ||
| 10/10 MUD + MFD | 28 (34) | 23 (34) | 3 (27) | ||
| MUD (9/10) | 5 (6) | 4 (6) | 1 (9) | ||
| MMD (CB + MMFD) | 17 (21) | 11 (16) | 4 (36) | ||
| CMV recipient-donor, n (%) | 70 (83) | .378 | |||
| −/− | 19 (27) | 16 (27) | 1 (14) | ||
| −/+ | 9 (13) | 8 (14) | 0 | ||
| +/− | 10 (14) | 7 (12) | 2 (29) | ||
| +/+ | 32 (46) | 28 (47) | 4 (57) | ||
| Conditioning regimen, n (%) | 81 (96) | .247 | |||
| Non-MA | 15 (19) | 14 (21) | 0 | ||
| MA | 66 (81) | 53 (79) | 10 (100) | ||
| Conditioning drugs, n (%) | 83 (99) | .205 | |||
| Bu based | 42 (51) | 36 (53) | 4 (36) | ||
| Bu + Cy | 17 (21) | 16 (24) | 1 (9) | ||
| Bu + Flu | 21 (25) | 18 (26) | 2 (18) | ||
| Bu + Flu + Cy | 1 (1) | 1 (1) | 0 | ||
| Bu + Flu + TT | 3 (4) | 1 (1) | 1 (9) | ||
| Treosulfan based | 26 (31) | 19 (28) | 6 (55) | ||
| Treo + Cy | 1 (1) | 1 (1) | 0 | ||
| Treo + Flu | 14 (17) | 13 (19) | 1 (9) | ||
| Treo + Flu + TT | 10 (12) | 4 (6) | 5 (45) | ||
| Treo + Mel + Flu | 1 (1) | 1 (1) | 0 | ||
| Others | 15 (18) | 13 (19) | 1 (9) | ||
| Mel + Flu | 13 (16) | 12 (18) | 0 | ||
| Mel + Flu + TT | 2 (2) | 1 (1) | 1 (9) | ||
| Serotherapy, n (%) | 83 (99) | .898 | |||
| No | 21 (25) | 18 (26) | 3 (27) | ||
| Yes | 62 (75) | 50 (74) | 8 (73) | ||
| ATG | 51 (61) | 41 (60) | 6 (55) | ||
| Alemtuzumab | 11 (13) | 9 (13) | 2 (18) | ||
| GVHD prophylaxis, n (%) | 80 (95) | .442 | |||
| No GvHD prevention | 2 (2) | 1 (2) | 1 (10) | ||
| Yes | 78 (98) | 65 (98) | 9 (90) | ||
| CSA alone | 20 (25) | 19 (29) | 1 (10) | ||
| CSA + corticosteroids | 8 (10) | 5 (8) | 1 (10) | ||
| CSA + MMF | 15 (19) | 10 (15) | 4 (40) | ||
| CSA + MTX | 27 (34) | 24 (36) | 2 (20) | ||
| Other | 8 (10) | 7 (11) | 1 (10) |
P values determined using Fisher's exact test or Wilcoxon-Mann-Whitney test as appropriate; missing values were excluded.
Cy, cyclophosphamide; Flu, fludarabine; Mel, melphalan; PB, peripheral blood; Treo, treosulfan, TT, thiotepa.